Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - methylphenidate hydrochloride 10mg;   - tablet - 10 mg - active: methylphenidate hydrochloride 10mg   excipient: calcium phosphate gelatin lactose monohydrate magnesium stearate purified talc wheat starch - ritalin/ritalin sr is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older. ritalin la is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older and in adults. ritalin/ritalin sr is indicated for the treatment of narcolepsy in adults. symptoms include daytime sleepiness, inappropriate sleep episodes, and sudden loss of voluntary muscle tone.

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - carbamazepine 200mg;  ;   - tablet - 200 mg - active: carbamazepine 200mg     excipient: carmellose sodium colloidal silicon dioxide magnesium stearate microcrystalline cellulose - · epilepsy - complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalization. - generalized tonic-clonic seizures. mixed forms of seizures. tegretol® is suitable for both monotherapy and combination therapy. tegretol is usually not effective in absences (petit mal) and myoclonic seizures

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - carbamazepine 400mg;   - tablet - 400 mg - active: carbamazepine 400mg   excipient: carmellose sodium colloidal silicon dioxide magnesium stearate microcrystalline cellulose - · epilepsy - complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalization. - generalized tonic-clonic seizures. mixed forms of seizures. tegretol® is suitable for both monotherapy and combination therapy. tegretol is usually not effective in absences (petit mal) and myoclonic seizures

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - caffeine 100mg (anhydrous); ergotamine tartrate 1mg;  ;   - tablet - 100 mg/1 mg - active: caffeine 100mg (anhydrous) ergotamine tartrate 1mg     excipient: iron oxide yellow magnesium stearate microcrystalline cellulose purified talc starch tartaric acid - treatment of acute attacks of migraine with or without aura in adults.

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - chlortalidone 25mg;   - tablet - 25 mg - active: chlortalidone 25mg   excipient: colloidal silicon dioxide iron oxide red iron oxide yellow lactose monohydrate magnesium stearate maize starch purified talc - arterial hypertension, essential or nephrogenic or isolated systolic, as primary therapy or in combination with other antihypertensive agents. stable, chronic heart failure of mild to moderate degree (new york heart association, nhya: functional class ii or iii). - oedema of specific origin - oedema due to peripheral (chronic) venous insufficiency; short-term therapy if physical measures prove insufficient. - fluid retention in premenstrual syndrome only if the gain in weight is the main symptom and is well documented. - ascites due to cirrhosis of the liver in stable patients under close control. - oedema due to nephrotic syndrome. - prophylaxis against recurrent calcium oxalate calculi in patients with idiopathic, normocalcaemic hypercalciuria.

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - imatinib mesilate 119.5mg equivalent to imatinib base 100 mg;   - film coated tablet - 100 mg - active: imatinib mesilate 119.5mg equivalent to imatinib base 100 mg   excipient: colloidal silicon dioxide crospovidone hypromellose magnesium stearate microcrystalline cellulose opadry red 00f15613 opadry yellow 00f12951 purified water - · treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive chronic myeloid leukaemia (ph+cml). · treatment of adult and paediatic patients with ph+cml in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. · treatment of adult patients with new diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+all) integrated with chemotherapy. · treatment of adult patients with relapsed or refractory ph+all as monotherapy. · treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. · treatment of adult patients with systemic mastocytosis (sm) without the d816v c-kit mutation or with c-kit mutational status unknown. · treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel). · treatment of adult patients with kit+ (cd117) unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). · adjuvant treatment of adult patients following resection of kit+gist. · treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - imatinib mesilate 478mg equivalent to imatinib base 400 mg;   - film coated tablet - 400 mg - active: imatinib mesilate 478mg equivalent to imatinib base 400 mg   excipient: colloidal silicon dioxide crospovidone hypromellose magnesium stearate microcrystalline cellulose opadry red 00f15613 opadry yellow 00f12951 purified water - · treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive chronic myeloid leukaemia (ph+cml). · treatment of adult and paediatic patients with ph+cml in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. · treatment of adult patients with new diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+all) integrated with chemotherapy. · treatment of adult patients with relapsed or refractory ph+all as monotherapy. · treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. · treatment of adult patients with systemic mastocytosis (sm) without the d816v c-kit mutation or with c-kit mutational status unknown. · treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel). · treatment of adult patients with kit+ (cd117) unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). · adjuvant treatment of adult patients following resection of kit+gist. · treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - methylphenidate hydrochloride 20mg;  ;   - modified release tablet - 20 mg - active: methylphenidate hydrochloride 20mg     excipient: carbon dioxide carnauba wax cetostearyl alcohol hypromellose ink lactose monohydrate magnesium stearate methylated spirits polyethylene glycol hydrogenated castor oil purified talc purified water titanium dioxide - ritalin/ritalin sr is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older. ritalin la is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older and in adults. ritalin/ritalin sr is indicated for the treatment of narcolepsy in adults. symptoms include daytime sleepiness, inappropriate sleep episodes, and sudden loss of voluntary muscle tone.

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - metoprolol tartrate 200mg - modified release tablet - 200 mg - active: metoprolol tartrate 200mg excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide ethanol as ethanol with 5% isopropyl alcohol -not in final product glyceryl palmito-stearate hypromellose   iron oxide yellow magnesium stearate methacrylic acid copolymer as eudragit e 30 d microcrystalline cellulose polysorbate 80 purified talc purified water titanium dioxide - disturbances of cardiac rhythm, including supraventricular and ventricular arrhythmias.

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - carbamazepine 200mg;  ;   - modified release tablet - 200 mg - active: carbamazepine 200mg     excipient: carmellose sodium colloidal silicon dioxide ethylcellulose hypromellose yellow, red, white suspension iron oxide red iron oxide yellow magnesium stearate methacrylic acid copolymer microcrystalline cellulose polyethylene glycol hydrogenated castor oil purified talc   purified water titanium dioxide - epilepsy - complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalization. - generalized tonic-clonic seizures. mixed forms of seizures. tegretol® is suitable for both monotherapy and combination therapy. tegretol is usually not effective in absences (petit mal) and myoclonic seizures